• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

3'-螺环核苷,一类新型的特异性人类免疫缺陷病毒1型抑制剂:[2'-5'-双-O-(叔丁基二甲基甲硅烷基)-β-D-木糖呋喃糖和核糖呋喃糖]-3'-螺环-5"-[4"-氨基-1",2"-氧硫杂环戊烯2",2"-二氧化物](TSAO)嘧啶核苷的合成及抗病毒活性

3'-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2'-5'-bis-O-(tert-butyldimethylsilyl)-beta-D-xylo- and -ribofuranose]-3'-spiro-5"-[4"-amino-1",2"-oxathiole 2",2"-dioxide] (TSAO) pyrimidine nucleosides.

作者信息

Camarasa M J, Pérez-Pérez M J, San-Félix A, Balzarini J, De Clercq E

机构信息

Instituto de Química Médica, Juan de la Cierva, Madrid, Spain.

出版信息

J Med Chem. 1992 Jul 24;35(15):2721-7. doi: 10.1021/jm00093a002.

DOI:10.1021/jm00093a002
PMID:1495006
Abstract

A series of 3'-spiro nucleosides have been synthesized and evaluated as anti-HIV-1 agents. Reaction of O-mesylcyanohydrins of furanos-3'-ulosyl nucleosides with base afforded [1-[2',5'-bis-O- (tert-butyldimethylsilyl)-beta-D-xylo- and -ribofuranosyl]]-3'-spiro-5"- [4"-amino-1",2"-oxathiole 2",2"-dioxide] derivatives of thymine, uracil and 4-N-acetylcytosine 11 and 12. Desilylation of 11 and 12 gave the full deprotected 3'-spiro xylo- and ribofuranosyl nucleosides 13 and 14 or the partially 5'-O-deprotected-3'-spiro beta-D-xylo- and -ribo-nucleosides 15 and 16, or 2'-O-deprotected-3'-spiro beta-D-ribo-nucleoside 17. 2'-Deoxygenation of 17 afforded 2'-deoxy-3'-spiro beta-D-erythro-pentofuranosyl derivative 18. These 3'-spiro derivatives were evaluated for their anti-HIV-1 activity. All 3'-spiro nucleosides having a xylo configuration did not show any anti-HIV-1 activity. 3'-Spiro ribo-nucleosides with none or only one silyl group at C-2' or C-5' or the 2'-deoxy derivative were also inactive at subtoxic concentrations. However, 3'-spiro ribo-nucleosides having two silyl groups at C-2' and C-5' were potent and selective inhibitors of HIV-1. None of the nucleoside analogues that showed anti-HIV-1 activity proved inhibitory to the replication of HIV-2 or SIV.

摘要

已合成了一系列3'-螺核苷,并作为抗HIV-1药物进行了评估。呋喃糖-3'-酮糖基核苷的O-甲磺酰基氰醇与碱反应,得到胸腺嘧啶、尿嘧啶和4-N-乙酰胞嘧啶的[1-[2',5'-双-O-(叔丁基二甲基甲硅烷基)-β-D-木糖基和核糖呋喃糖基]]-3'-螺-5"-[4"-氨基-1",2"-氧硫杂环戊烷2",2"-二氧化物]衍生物11和12。11和12的脱硅反应得到完全脱保护的3'-螺木糖基和核糖呋喃糖基核苷13和14,或部分5'-O-脱保护的-3'-螺β-D-木糖基和核糖核苷15和16,或2'-O-脱保护的-3'-螺β-D-核糖核苷17。17的2'-脱氧反应得到2'-脱氧-3'-螺β-D-赤藓戊呋喃糖基衍生物18。对这些3'-螺衍生物的抗HIV-1活性进行了评估。所有具有木糖构型的3'-螺核苷均未显示出任何抗HIV-1活性。在C-2'或C-5'处没有或只有一个甲硅烷基的3'-螺核糖核苷或2'-脱氧衍生物在亚毒性浓度下也没有活性。然而,在C-2'和C-5'处具有两个甲硅烷基的3'-螺核糖核苷是HIV-1的有效和选择性抑制剂。没有一种显示抗HIV-1活性的核苷类似物被证明对HIV-2或SIV的复制有抑制作用。

相似文献

1
3'-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2'-5'-bis-O-(tert-butyldimethylsilyl)-beta-D-xylo- and -ribofuranose]-3'-spiro-5"-[4"-amino-1",2"-oxathiole 2",2"-dioxide] (TSAO) pyrimidine nucleosides.3'-螺环核苷,一类新型的特异性人类免疫缺陷病毒1型抑制剂:[2'-5'-双-O-(叔丁基二甲基甲硅烷基)-β-D-木糖呋喃糖和核糖呋喃糖]-3'-螺环-5"-[4"-氨基-1",2"-氧硫杂环戊烯2",2"-二氧化物](TSAO)嘧啶核苷的合成及抗病毒活性
J Med Chem. 1992 Jul 24;35(15):2721-7. doi: 10.1021/jm00093a002.
2
TSAO analogues. 3. Synthesis and anti-HIV-1 activity of 2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl 3'-spiro-5''-(4''-amino-1'',2''-oxathiole 2'',2''-dioxide) purine and purine-modified nucleosides.曹(TSAO)类似物。3. 2',5'-双-O-(叔丁基二甲基甲硅烷基)-β-D-呋喃核糖基3'-螺-5''-(4''-氨基-1'',2''-氧硫杂环戊烯2'',2''-二氧化物)嘌呤及嘌呤修饰核苷的合成与抗HIV-1活性
J Med Chem. 1993 Oct 29;36(22):3230-9. doi: 10.1021/jm00074a003.
3
TSAO analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro -5''- (4''-amino-1'',2''-oxathiole 2'',2''-dioxide) pyrimidine and pyrimidine-modified nucleosides.TSAO类似物。1-[2',5'-双-O-(叔丁基二甲基甲硅烷基)-β-D-呋喃核糖基]-3'-螺-5''-(4''-氨基-1'',2''-氧硫杂环戊烯2'',2''-二氧化物)嘧啶及嘧啶修饰核苷的立体定向合成与抗HIV-1活性
J Med Chem. 1992 Aug 7;35(16):2988-95. doi: 10.1021/jm00094a009.
4
[2',5'-Bis-O-(tert-butyldimethylsilyl)]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) (TSAO) derivatives of purine and pyrimidinenucleosides as potent and selective inhibitors of human immunodeficiency virus type 1.嘌呤和嘧啶核苷的[2',5'-双-O-(叔丁基二甲基甲硅烷基)]-3'-螺-5''-(4''-氨基-1'',2''-氧硫杂环戊烯-2'',2''-二氧化物)(TSAO)衍生物作为1型人类免疫缺陷病毒的有效和选择性抑制剂。
Antimicrob Agents Chemother. 1992 May;36(5):1073-80. doi: 10.1128/AAC.36.5.1073.
5
Synthesis and antiviral activity of 3'-C-cyano-3'-deoxynucleosides.
J Med Chem. 1989 Aug;32(8):1732-8. doi: 10.1021/jm00128a011.
6
Novel series of TSAO-T derivatives. Synthesis and anti-HIV-1 activity of 4-, 5-, and 6-substituted pyrimidine analogues.新型TSAO-T衍生物系列。4-、5-和6-取代嘧啶类似物的合成及抗HIV-1活性。
J Med Chem. 1994 Feb 18;37(4):453-60. doi: 10.1021/jm00030a004.
7
2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase.2',5'-双-O-(叔丁基二甲基甲硅烷基)-3'-螺-5''-(4''-氨基-1'',2''-氧硫杂环戊烯-2'',2'-二氧化物)嘧啶(TSAO)核苷类似物:针对人类免疫缺陷病毒1型的高度选择性抑制剂,作用于病毒逆转录酶。
Proc Natl Acad Sci U S A. 1992 May 15;89(10):4392-6. doi: 10.1073/pnas.89.10.4392.
8
1,2,3-Triazole-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D- ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"-oxathiole 2",2"-dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity.1,2,3-三唑-[2',5'-双-O-(叔丁基二甲基甲硅烷基)-β-D-呋喃核糖基]-3'-螺-5"-(4"-氨基-1",2"-氧硫杂环戊烯2",2"-二氧化物)(TSAO)类似物:合成及抗HIV-1活性
J Med Chem. 1994 Nov 25;37(24):4185-94. doi: 10.1021/jm00050a015.
9
Human immunodeficiency virus type 1-specific [2',5'-bis-O-(tert- butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"- oxathiole-2",2"-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1-specific non-nucleoside analogues.1型人类免疫缺陷病毒特异性的[2',5'-双-O-(叔丁基二甲基甲硅烷基)-β-D-呋喃核糖基]-3'-螺-5"-(4"-氨基-1",2"-氧硫杂环戊二烯-2",2"-二氧化物)-嘌呤类似物显示出与1型人类免疫缺陷病毒特异性非核苷类似物不同的耐药谱。
Mol Pharmacol. 1993 Jan;43(1):109-14.
10
Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors.针对HIV-1特异性[2',5'-双-O-(叔丁基二甲基甲硅烷基)-3'-螺-5''-(4''-氨基-1'',2''-氧硫杂环戊烯-2'',2''-二氧化物)]-β-D-戊呋喃糖基(TSAO)核苷类似物产生耐药性的1型人类免疫缺陷病毒(HIV-1)毒株,对HIV-1特异性非核苷抑制剂仍保持敏感。
Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):6952-6. doi: 10.1073/pnas.90.15.6952.

引用本文的文献

1
The role of silicon in drug discovery: a review.硅在药物发现中的作用:综述
RSC Med Chem. 2024 Jul 1;15(10):3286-3344. doi: 10.1039/d4md00169a. eCollection 2024 Oct 17.
2
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.叔丁基二甲基硅基螺环氨基氧硫代二氧噻嗪-胸腺嘧啶(TSAO-T)与 HIV-1 逆转录酶(RT)复合物的晶体结构重新定义了非核苷抑制剂结合口袋的弹性极限。
J Med Chem. 2011 Apr 28;54(8):2727-37. doi: 10.1021/jm101536x. Epub 2011 Mar 29.
3
Exploitation of the low fidelity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and the nucleotide composition bias in the HIV-1 genome to alter the drug resistance development of HIV.
利用人类免疫缺陷病毒1型(HIV-1)逆转录酶的低保真性以及HIV-1基因组中的核苷酸组成偏向性来改变HIV的耐药性发展。
J Virol. 2001 Jul;75(13):5772-7. doi: 10.1128/JVI.75.13.5772-5777.2001.
4
Novel ribofuranosylnucleoside lead compounds for potent and selective inhibitors of mitochondrial thymidine kinase-2.用于线粒体胸苷激酶-2的强效和选择性抑制剂的新型呋喃核糖核苷先导化合物。
Biochem J. 2000 Oct 1;351(Pt 1):167-71. doi: 10.1042/0264-6021:3510167.
5
Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1.在HIV-1喹喔啉剂量递增治疗的选择压力下出现的人类免疫缺陷病毒1型(HIV-1)逆转录酶Pro225His突变的特征。
J Virol. 1997 Nov;71(11):8195-203. doi: 10.1128/JVI.71.11.8195-8203.1997.
6
Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.嘌呤和嘧啶衍生物的抗逆转录病毒作用的代谢与机制
Pharm World Sci. 1994 Apr 15;16(2):113-26. doi: 10.1007/BF01880662.
7
Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.用1型人类免疫缺陷病毒(HIV-1)特异性抑制剂组合治疗HIV-1感染的细胞,会产生与单药治疗不同的耐药模式。
J Virol. 1993 Sep;67(9):5353-9. doi: 10.1128/JVI.67.9.5353-5359.1993.
8
Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors.针对HIV-1特异性[2',5'-双-O-(叔丁基二甲基甲硅烷基)-3'-螺-5''-(4''-氨基-1'',2''-氧硫杂环戊烯-2'',2''-二氧化物)]-β-D-戊呋喃糖基(TSAO)核苷类似物产生耐药性的1型人类免疫缺陷病毒(HIV-1)毒株,对HIV-1特异性非核苷抑制剂仍保持敏感。
Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):6952-6. doi: 10.1073/pnas.90.15.6952.
9
Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives).硫代羧酰苯胺衍生物单独使用或与其他HIV-1特异性抑制剂(即TSAO衍生物)联合使用时对细胞培养中1型人类免疫缺陷病毒(HIV-1)突破的抑制作用。
Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5470-4. doi: 10.1073/pnas.92.12.5470.
10
Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720.1型人类免疫缺陷病毒逆转录酶对喹喔啉S-2720的耐药模式
J Virol. 1994 Dec;68(12):7986-92. doi: 10.1128/JVI.68.12.7986-7992.1994.